Professional Experience
GSK Vaccines, Slaoui Center for Vaccines Research, Rockville, MD
Associate Scientist
Sep. 2017 – Aug. 2020
Projects worked on:
GSK3844766A (RSV) – Older Adult – Recombinant Protein adjuvanted
GSK3888550A (RSV) – Maternal – Recombinant Protein
Platform Technologies (SAM) – Self-Amplifying Messenger RNA
Adjuvant Technologies (Alum-TLR7) – TLR7 agonist adsorbed to alum
Cross-functional activities
Analytical UltraCentrifugation (AUC)
Common lab techniques (Densitometry, Osmolality, pH, UV-Vis, Viscosity)
Dynamic Light Scattering (DLS)
Förster Resonance Energy Transfer (FRET)
Fourier-transform infrared spectroscopy (FTIR)
Lyophilization
Nanoparticle Tracking Analysis (NTA)
Surface Plasmon Resonance (SPR)
Tangential Flow Filtration (TFF)
Ultra and High Performance Liquid Chromatography (UPLC/HPLC)
· Reverse Phase chromatography (RP)
· Size Exclusion Chromatography (SEC)
X-Ray Powder Diffraction (XRD)
Software used:
Biacore T200 Control (SPR)
Blender (3D Modeling)
DIFFRAC.SUITE (XRD)
Empower (UPLC/HPLC)
Inkscape (Figures – SVG files)
JMP (statistical software)
KrosFlo KR2i – Repligen Control (TFF)
Microsoft Office
· Excel, PowerPoint, Word
NanoSight NTA (NTA)
OMNIC (FTIR)
Origin (OriginLab)
PyMOL
SAP GUI
SedFit (AUC)
Sednterp (AUC)
SoftMax (UV-Vis, FRET)
Trimble Sketch-up (3D Modeling)
Ultimaker Cura (3D Printing)
Zetasizer Nano software (DLS)
Technical reports authored:
Comparability Template used for future IND submissions
RSV Drug Product Process Description for Technical Transfer
RSV Production Report for Process Compatibility Study
RSV Production Summary Report for Toxicology and Clinical Studies
SAM Process and Product Comparability Report for Development and Clinical Trial Material
SAM Process and Product Comparability Report for Toxicology and GMP Drug Product Lots
SAM Diluent Stability Report
Composition of RSV Phase III Drug Product and Reconstituted Vaccine
Addendum for RSV Phase III Placebo and Reconstituted Placebo
RSV Platform Placebo Proposal
RSV Adjuvant Compatibility for Phase III Formulation
RSV In-Use Stability for Phase III Formulation
Leadership Skills displayed:
Led the Following Studies
SAM Diluent Stability
RSV Platform Placebo
RSV Adjuvant Compatibility
RSV In-Use Stability
Appointed Lead User of the liquid chromatography lab
Responsibilities: – maintaining and managing all instruments (– perform routine maintenance and cleanings – manage maintenance schedules – troubleshoot issues for all users) – training all users on new and current methods
Appointed Representative for Alignment meetings between R&D and GMP manufacturing
Authored: – Template for technical transfers – Process mapping documents
Appointed to lead 5S Initiative to organize and maintain the Drug Product Development lab space
Achievements: – Set the standards and authored the model used for all 5S initiatives in other departments – Awarded Global Employee Recognition for having a major impact outside of working group
US Representative for all 3D printing activities
Deliverables: – 3D Printer Workshop – Developed models used to improve the efficiency of lab activities and used to improve the organization, cleanliness, and safety of the lab – Developed molecular models for visualization and to use as presentation tools
Awards:
Global Employee Recognition: Silver
Feb 2019: Led 5S Initiative in Drug Product Development Labs; silver awarded for having a major impact outside of working group
Global Employee Recognition: Bronze
Aug 2020: Led the TFF process (core unit operation) to produce a toxicology batch in development space for the first time in this department's history. This includes all preparation of documents related to this process, execution of the process, and thorough real-time documentation using GMP-like standards. (SAM)
July 2020: Evaluated necessary options and met with suppliers to replace a piece of high value equipment (~$1M USD) in order to enable toxicology lot production within developmental labs. Compiled information into a proposal for the department's 2021 PIP budget.
June 2020: Led an adjuvant compatibility and in-use study including designing, planning, executing, and summarizing the analytical results in a report to support the Phase III regulatory filing (RSV)
Apr 2019: Independently executed stability study, collected all data, and provided interim stability reports; ultimately supported self-life extension (SAM)
Dec 2018: Presentation and demonstration on 3D printing at R&D Days
Aug 2018: Supported critical activities needed to ensure successful manufacture of the first clinical drug product batch (RSV)
GSK Vaccines, Marietta, PA
FFL Operator
Jul. 2015 - Aug. 2017
All details related to formulations and documents written are confidential and not included
Vaccines formulated:
MMR, Varilrix (varicella)
Job requirements:
Carried out secondary production of lyophilized vaccines by following Standard Operating Procedures (SOPs), kept up with current Good Manufacturing Processes (cGMP), used aseptic technique in classified areas (Grade A/B/C/D).
Equipment used:
Bosch vial filler, lyophilizer, Bosch vial washer, Bosch vial capper, Seidenader automated visual inspection, stainless steel vessels (sizes: 5L - 85L), peristaltic pumps
Technical documents written/reviewed:
Master Batch Production Records, Investigations, Deviations, Standard Operating Procedures, Job Safety Assessments, Job Aids